Home > bluebird bio

US FDA Approves bluebird bio’s Gene Therapy ZYNTEGLO

bluebird bio, Inc. announced the US Food and Drug Administration (FDA) has approved ZYNTEGLO, a one-time gene therapy, which is custom-designed to treat the underlying genetic cause of the beta-thalassemia in the adult and pediatric patients who now require regular red blood cell (RBC) transfusions. Andrew Obenshain, chief executive officer of

Read More